• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.通过氢胺化反应实现的酶抑制作用:一种卡马霉素 - 丁香霉素烯酮杂合蛋白酶体抑制剂的设计与作用机制
Chem Biol. 2014 Jun 19;21(6):782-91. doi: 10.1016/j.chembiol.2014.04.010. Epub 2014 Jun 12.
2
Design, Synthesis, and Biological Activity of Isosyringolin A.异丁香脂素 A 的设计、合成与生物活性
Org Lett. 2016 May 6;18(9):2312-5. doi: 10.1021/acs.orglett.6b01053. Epub 2016 Apr 28.
3
Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.作为20S蛋白酶体抑制剂的C端萘醌二肽的研究。
J Enzyme Inhib Med Chem. 2016;31(3):456-63. doi: 10.3109/14756366.2015.1037749. Epub 2015 May 5.
4
Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.探索卡玛霉素作为抗体药物偶联物抗癌药物的有效载荷。
Eur J Med Chem. 2019 Jan 1;161:416-432. doi: 10.1016/j.ejmech.2018.10.024. Epub 2018 Oct 15.
5
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.以β-氨基酸构建的新型三肽基环氧酮衍生物作为蛋白酶体抑制剂的设计、合成及生物学评价
Bioorg Med Chem. 2014 Jun 1;22(11):2955-65. doi: 10.1016/j.bmc.2014.04.011. Epub 2014 Apr 13.
6
Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.活性增强的合成 Syrbactin 蛋白酶体抑制剂杂合体及其在肿瘤细胞中的生物学评价。
Biochemistry. 2012 Aug 28;51(34):6880-8. doi: 10.1021/bi300841r. Epub 2012 Aug 17.
7
Structure-activity relationship study of syringolin A as a potential anticancer agent.紫丁香菌素A作为一种潜在抗癌剂的构效关系研究。
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4872-4877. doi: 10.1016/j.bmcl.2015.06.015. Epub 2015 Jun 17.
8
Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells.基于天然蛋白酶体抑制剂衍生物的小分子药物偶联物的开发,这些衍生物对表达 PSMA 的癌细胞具有选择性。
Bioorg Med Chem. 2024 Jun 15;108:117773. doi: 10.1016/j.bmc.2024.117773. Epub 2024 Jun 3.
9
Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.由β-氨基酸组成的肽基环氧酮蛋白酶体抑制剂的设计、合成及生物学评价
Chem Biol Drug Des. 2014 Nov;84(5):497-504. doi: 10.1111/cbdd.12342. Epub 2014 Jun 3.
10
Structure-based design of human immuno- and constitutive proteasomes inhibitors.基于结构的人免疫和组成型蛋白酶体抑制剂的设计。
Eur J Med Chem. 2018 Feb 10;145:570-587. doi: 10.1016/j.ejmech.2018.01.013. Epub 2018 Jan 8.

引用本文的文献

1
Progress in the discovery and development of anticancer agents from marine cyanobacteria.从海洋蓝细菌中发现和开发抗癌药物的进展。
Nat Prod Rep. 2025 Feb 19;42(2):208-256. doi: 10.1039/d4np00019f.
2
Evaluating Antimalarial Proteasome Inhibitors for Efficacy in Blood Stage Cultures.评估抗疟蛋白酶体抑制剂在血液阶段培养物中的疗效。
ACS Omega. 2024 Oct 28;9(45):44989-44999. doi: 10.1021/acsomega.4c04564. eCollection 2024 Nov 12.
3
Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome.解码秘密:构象和结构调节剂如何抑制人20S蛋白酶体。
Front Chem. 2024 Jan 8;11:1322628. doi: 10.3389/fchem.2023.1322628. eCollection 2023.
4
Stereospecific Conversion of Boronic Esters into Enones using Methoxyallene: Application in the Total Synthesis of 10-Deoxymethynolide.使用甲氧基丙二烯将硼酸酯立体定向转化为烯酮:在10-脱氧甲炔诺内酯全合成中的应用。
Angew Chem Int Ed Engl. 2023 Dec 11;62(50):e202312054. doi: 10.1002/anie.202312054. Epub 2023 Nov 9.
5
Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics.天然产物骨架作为潜在蛋白酶体抑制剂在癌症治疗药物研发中的演变
Metabolites. 2023 Mar 31;13(4):509. doi: 10.3390/metabo13040509.
6
Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.通过共价双重亚单位抑制疟原虫蛋白酶体来降低抗疟药物耐药性的风险。
Cell Chem Biol. 2023 May 18;30(5):470-485.e6. doi: 10.1016/j.chembiol.2023.03.002. Epub 2023 Mar 23.
7
Novel Class of Proteasome Inhibitors: In Silico and In Vitro Evaluation of Diverse Chloro(trifluoromethyl)aziridines.新型蛋白酶体抑制剂:多种氯(三氟甲基)氮丙啶的计算机模拟和体外评估
Int J Mol Sci. 2022 Oct 15;23(20):12363. doi: 10.3390/ijms232012363.
8
Bromoditerpenes from the Red Seaweed as Potential Cytotoxic Agents and Proteasome Inhibitors and Related Mechanisms of Action.红海藻类中的溴二萜类化合物作为潜在的细胞毒性剂和蛋白酶体抑制剂及相关作用机制。
Mar Drugs. 2022 Oct 20;20(10):652. doi: 10.3390/md20100652.
9
Production of Epoxyketone Peptide-Based Proteasome Inhibitors by sp. BRA-346: Regulation and Biosynthesis.sp. BRA-346产生基于环氧酮肽的蛋白酶体抑制剂:调控与生物合成。
Front Microbiol. 2022 Mar 24;13:786008. doi: 10.3389/fmicb.2022.786008. eCollection 2022.
10
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.天然产物骨架作为设计和合成20S人蛋白酶体抑制剂的灵感来源。
RSC Chem Biol. 2020 Dec 1;1(5):305-332. doi: 10.1039/d0cb00111b. Epub 2020 Sep 16.

本文引用的文献

1
Assessment of the Performance of the M05-2X and M06-2X Exchange-Correlation Functionals for Noncovalent Interactions in Biomolecules.评估 M05-2X 和 M06-2X 交换相关泛函在生物分子中非共价相互作用中的性能。
J Chem Theory Comput. 2008 Dec 9;4(12):1996-2000. doi: 10.1021/ct800308k. Epub 2008 Nov 19.
2
Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.环氧酮蛋白酶体抑制剂类药物的生物合成的遗传基础。
ACS Chem Biol. 2014 Jan 17;9(1):301-9. doi: 10.1021/cb400699p. Epub 2013 Nov 8.
3
Fundamental reaction pathway and free energy profile for inhibition of proteasome by Epoxomicin.环氧酶抑制剂对蛋白酶体抑制的基本反应途径和自由能态势。
J Am Chem Soc. 2012 Jun 27;134(25):10436-50. doi: 10.1021/ja3006463. Epub 2012 Jun 14.
4
The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.卡马西平:一种新型蛋白酶体抑制剂,来自海洋蓝藻,具有 α,β-环氧酮弹头。
Chembiochem. 2012 Apr 16;13(6):810-7. doi: 10.1002/cbic.201200007. Epub 2012 Mar 1.
5
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.利用动力学和X射线晶体学研究分析蛋白酶体抑制剂的特性。
Methods Mol Biol. 2012;832:373-90. doi: 10.1007/978-1-61779-474-2_26.
6
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity.免疫和组成型蛋白酶体晶体结构揭示了底物和抑制剂特异性的差异。
Cell. 2012 Feb 17;148(4):727-38. doi: 10.1016/j.cell.2011.12.030.
7
Proteasome inhibitors: an expanding army attacking a unique target.蛋白酶体抑制剂:一支不断壮大的攻击独特靶点的队伍。
Chem Biol. 2012 Jan 27;19(1):99-115. doi: 10.1016/j.chembiol.2012.01.003.
8
Molecular pathways: targeting proteasomal protein degradation in cancer.分子通路:在癌症中靶向蛋白酶体蛋白降解。
Clin Cancer Res. 2012 Jan 1;18(1):15-20. doi: 10.1158/1078-0432.CCR-11-0853. Epub 2011 Oct 21.
9
Cytotoxic veraguamides, alkynyl bromide-containing cyclic depsipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera.细胞毒性的韦拉古胺类化合物,来自海洋蓝藻 cf. 珍珠硷旋藻的含炔基溴的环状缩肽。
J Nat Prod. 2011 May 27;74(5):928-36. doi: 10.1021/np200077f. Epub 2011 Apr 13.
10
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.蛋白酶体抑制剂硼替佐米和卡非佐米的非蛋白酶体靶标:与临床不良事件的关联。
Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.

通过氢胺化反应实现的酶抑制作用:一种卡马霉素 - 丁香霉素烯酮杂合蛋白酶体抑制剂的设计与作用机制

Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.

作者信息

Trivella Daniela B B, Pereira Alban R, Stein Martin L, Kasai Yusuke, Byrum Tara, Valeriote Frederick A, Tantillo Dean J, Groll Michael, Gerwick William H, Moore Bradley S

机构信息

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093-0212, USA; Institute of Chemistry, University of Campinas, Campinas SP 13083-970, Brazil; Brazilian Biosciences National Laboratory, National Center for Research in Energy and Materials, Campinas SP 13083-970, Brazil.

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093-0212, USA.

出版信息

Chem Biol. 2014 Jun 19;21(6):782-91. doi: 10.1016/j.chembiol.2014.04.010. Epub 2014 Jun 12.

DOI:10.1016/j.chembiol.2014.04.010
PMID:24930969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4103027/
Abstract

Hydroamination reactions involving the addition of an amine to an inactivated alkene are entropically prohibited and require strong chemical catalysts. While this synthetic process is efficient at generating substituted amines, there is no equivalent in small molecule-mediated enzyme inhibition. We report an unusual mechanism of proteasome inhibition that involves a hydroamination reaction of alkene derivatives of the epoxyketone natural product carmaphycin. We show that the carmaphycin enone first forms a hemiketal intermediate with the catalytic Thr1 residue of the proteasome before cyclization by an unanticipated intramolecular alkene hydroamination reaction, resulting in a stable six-membered morpholine ring. The carmaphycin enone electrophile, which does not undergo a 1,4-Michael addition as previously observed with vinyl sulfone and α,β-unsaturated amide-based inhibitors, is partially reversible and gives insight into the design of proteasome inhibitors for cancer chemotherapy.

摘要

涉及将胺加成到钝化烯烃上的氢胺化反应在熵上是被禁止的,并且需要强化学催化剂。虽然这种合成过程在生成取代胺方面很有效,但在小分子介导的酶抑制中却没有类似的情况。我们报道了一种不寻常的蛋白酶体抑制机制,该机制涉及环氧酮天然产物卡马霉素的烯烃衍生物的氢胺化反应。我们表明,卡马霉素烯酮首先与蛋白酶体的催化性苏氨酸1残基形成半缩酮中间体,然后通过意外的分子内烯烃氢胺化反应环化,形成稳定的六元吗啉环。卡马霉素烯酮亲电试剂不像之前观察到的乙烯基砜和基于α,β-不饱和酰胺的抑制剂那样发生1,4-迈克尔加成,它是部分可逆的,这为癌症化疗用蛋白酶体抑制剂的设计提供了思路。